SONAR (2019) — Trial Summary
SONAR (2019): Double-blind, randomized, placebo-controlled trial of atrasentan versus placebo in adults with type 2 diabetes and CKD who completed an enrichment period showing albuminuria reduction without excess fluid retention (NCT01858532). Primary composite: doubling of serum creatinine or end-s
References
- Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937-1947.